BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34426438)

  • 1. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
    Hajda J; Leuchs B; Angelova AL; Frehtman V; Rommelaere J; Mertens M; Pilz M; Kieser M; Krebs O; Dahm M; Huber B; Engeland CE; Mavratzas A; Hohmann N; Schreiber J; Jäger D; Halama N; Sedlaczek O; Gaida MM; Daniel V; Springfeld C; Ungerechts G
    Clin Cancer Res; 2021 Oct; 27(20):5546-5556. PubMed ID: 34426438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.
    Hajda J; Lehmann M; Krebs O; Kieser M; Geletneky K; Jäger D; Dahm M; Huber B; Schöning T; Sedlaczek O; Stenzinger A; Halama N; Daniel V; Leuchs B; Angelova A; Rommelaere J; Engeland CE; Springfeld C; Ungerechts G
    BMC Cancer; 2017 Aug; 17(1):576. PubMed ID: 28851316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
    Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
    Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
    Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
    Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
    Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.
    Dempe S; Lavie M; Struyf S; Bhat R; Verbeke H; Paschek S; Berghmans N; Geibig R; Rommelaere J; Van Damme J; Dinsart C
    Cancer Immunol Immunother; 2012 Nov; 61(11):2113-23. PubMed ID: 22576056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of NK cell antitumor responses using an oncolytic parvovirus.
    Bhat R; Dempe S; Dinsart C; Rommelaere J
    Int J Cancer; 2011 Feb; 128(4):908-19. PubMed ID: 20473905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
    Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
    J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
    Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
    Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.
    Nakao A; Kasuya H; Sahin TT; Nomura N; Kanzaki A; Misawa M; Shirota T; Yamada S; Fujii T; Sugimoto H; Shikano T; Nomoto S; Takeda S; Kodera Y; Nishiyama Y
    Cancer Gene Ther; 2011 Mar; 18(3):167-75. PubMed ID: 21102422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment?
    Tassone E; Muscolini M; van Montfoort N; Hiscott J
    Cytokine Growth Factor Rev; 2020 Dec; 56():141-148. PubMed ID: 32859494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
    Haller SD; Monaco ML; Essani K
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic activity of avian influenza virus in human pancreatic ductal adenocarcinoma cell lines.
    Kasloff SB; Pizzuto MS; Silic-Benussi M; Pavone S; Ciminale V; Capua I
    J Virol; 2014 Aug; 88(16):9321-34. PubMed ID: 24899201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
    Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
    BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.